A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

被引：0
|
作者：
Gary H. Lyman
Stephanie J. Green
Peter M. Ravdin
Charles E. Geyer
Christy A. Russell
Stanley P. Balcerzak
G. Thomas Budd
Silvana Martino
机构：
[1] University of Rochester Medical Center,James P. Wilmot Cancer Center
[2] University of Rochester School of Medicine,undefined
[3] Strong Memorial Hospital,undefined
[4] Southwest Oncology Group Statistical Center,undefined
[5] University of Texas Health Science Center,undefined
[6] University of Southern California,undefined
[7] Ohio State University,undefined
[8] Cleveland Clinic,undefined
[9] John Wayne Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2004年 / 85卷
关键词：
doxorubicin; metastatic breast cancer; paclitaxel; phase II; SWOG;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [1] A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
    Lyman, GH
    Green, SJ
    Ravdin, PM
    Geyer, CE
    Russell, CA
    Balcerzak, SP
    Budd, GT
    Martino, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (02) : 143 - 150
  • [2] Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study
    Charles E. Geyer
    Stephanie J. Green
    Carol M. Moinpour
    Janet O'Sullivan
    Donna K. Goodwin
    Vikki A. Canfield
    Frederick J. Meyers
    C. Kent Osborne
    Silvana Martino
    Breast Cancer Research and Treatment, 1998, 51 : 169 - 181
  • [3] Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study
    Geyer, CE
    Green, SJ
    Moinpour, CM
    O'Sullivan, J
    Goodwin, DK
    Canfield, VA
    Meyers, FJ
    Osborne, CK
    Martino, S
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (02) : 169 - 181
  • [4] Phase II study of semisynthetic paclitaxel in metastatic breast cancer
    Hudis, C
    Riccio, L
    Holmes, F
    Seidman, A
    Baselga, J
    Currie, V
    Fennelly, D
    Gilewski, T
    Moynahan, M
    Raptis, G
    Sklarin, N
    Surbone, A
    Uhlenhopp, M
    Maickel, N
    Yao, TJ
    Hellman, S
    Usakewicz, J
    Hortobagyi, G
    Norton, L
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) : 2198 - 2202
  • [5] Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
    Alessandro Passardi
    Ilaria Massa
    Wainer Zoli
    Lorenzo Gianni
    Carlo Milandri
    Federica Zumaglini
    Oriana Nanni
    Roberta Maltoni
    Giovanni Luca Frassineti
    Dino Amadori
    BMC Cancer, 6
  • [6] Paclitaxel and mitoxantrone in metastatic breast cancer: A phase II trial of the Italian Oncology Group for Cancer Research
    Di Costanzo, F
    Manzione, L
    Gasperoni, S
    Bilancia, D
    Acito, L
    Angiona, S
    Mazzoni, F
    Giustini, L
    CANCER INVESTIGATION, 2004, 22 (03) : 331 - 337
  • [7] Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study
    Shao, Bin
    Song, Guohong
    Li, Huiping
    Di, Lijun
    Jiang, Hanfang
    Liang, Xu
    Yan, Ying
    Zhang, Ruyan
    Ran, Ran
    Wang, Jing
    Liu, Xiaoran
    You, Miaoning
    JOURNAL OF BUON, 2018, 23 (06): : 1583 - 1590
  • [8] Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
    Morris, Patrick G.
    Rota, Selene
    Cadoo, Karen
    Zamora, Stephen
    Patil, Sujata
    D'Andrea, Gabriella
    Gilewski, Theresa
    Bromberg, Jacqueline
    Dang, Chau
    Dickler, Maura
    Modi, Shanu
    Seidman, Andrew D.
    Sklarin, Nancy
    Norton, Larry
    Hudis, Clifford A.
    Fornier, Monica N.
    CLINICAL BREAST CANCER, 2018, 18 (05) : 387 - 394
  • [9] Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer:: a phase II study by the Hellenic Cooperative Oncology Group
    Gogas, H
    Papadimitriou, C
    Kalofonos, HP
    Bafaloukos, D
    Fountzilas, G
    Tsavdaridis, D
    Anagnostopoulos, A
    Onyenadum, A
    Papakostas, P
    Economopoulos, T
    Christodoulou, C
    Kosmidis, P
    Markopoulos, C
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1737 - 1742
  • [10] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
12345